TNFRSF4 and prostate cancer: Immune-activating role of RT was evident also in the NCT01303705 phase I clinical trial of castration-resistant prostate cancer where the treatment groups received 8 Gy RT prior to combination with immune activating OX40 (CD134) stimulation with different doses of cyclophosphamide.